Srihari S. Naidu, MD, FACC, FSCAI


Director, Cardiac Catheterization Laboratory, Interventional Cardiology Fellowship Program & Hypertrophic Cardiomyopathy Treatment Center at Winthrop University Hospital, Mineola, NY



  • Tenured Associate Professor of Medicine - SUNY Stony Brook School of Medicine
  • Past Trustee - Society for Cardiovascular Angiography and Interventions (SCAI)
  • Trustee - Brown University, Providence, Rhode Island
  • Chair and Founder - SCAI Emerging Leader Mentorship (ELM) Program
  • Past President - Brown University Medical Alumni Association


Srihari S. Naidu, MD, is an interventional cardiologist with expertise in atrial septal defect (ASD) and patent foramen ovale (PFO) closure, alcohol septal ablation for hypertrophic obstructive cardiomyopathy, aortic and mitral valvuloplasty (and mitraclip percutaneous valve repair), ventricular assist devices, and coronary intervention including angioplasty and stent placement.  He is Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology, and is a Tenured Associate Professor of Medicine at SUNY - Stony Brook School of Medicine.

Prior to joining Winthrop University Hospital in 2006, Dr. Naidu was an Assistant Professor of Medicine at New York Presbyterian Hospital - Weill Cornell Medical Center. Dr. Naidu developed the Hypertrophic Cardiomyopathy Treatment Center at Cornell, performing their first series of alcohol septal ablations.  Dr. Naidu trained in Internal Medicine at Cornell, and General and Interventional Cardiology at the University of Pennsylvania.  

A graduate of the 8-year Program in Liberal Medical Education at Brown University, Dr. Naidu is Past President of the Medical School Board of Directors, and Reunion Chair of the Undergraduate Class of 1993.   (  In 2013, he was elected a Trustee of Brown University.

Under Dr. Naidu's leadership, the Cardiac Catheterization Laboratory at Winthrop University Hospital has grown in procedural volume, breadth of procedures, and regional and national reputation, while maintaining the highest quality outcomes.  Significantly, the lab has developed a track record for bringing the latest technologies and techniques to Long Island before other hospitals, including the first implantation of Xience and Endeavor drug-eluting stents, the first Impella ventricular assist device for high-risk angioplasty, and one of the highest volume centers using minimally-invasive techniques to replace (TAVR) or repair (Mitraclip) heart valves.  In addition, Dr. Naidu and his team perform more ASD/PFO closures and alcohol septal ablations, with a proven track record of high quality and success, than any other adult interventional cardiologist on Long Island.

A Fellow of the American College of Cardiology (FACC), American Heart Association (FAHA), and Society for Cardiovascular Angiography and Interventions (FSCAI), Dr. Naidu serves on several prestigious national committees, including the ACC Interventional Science Council (two term member) and Curriculum Development Work Group, and is an Associate Director for TCT.  Dr. Naidu Founded and Chairs the SCAI Emerging Leader Mentorship (ELM) Program in partnership with ACC and the Cardiovascular Research Foundation (CRF), a dedicated interventional leadership pipeline that selects and mentors 10 interventional cardiologists every 2 years for national leadership roles.  More information on the ELM Program may be found at  He is a Past Trustee of SCAI.


Dr. Naidu has over 100 scientific publications dealing with angioplasty outcomes, new technology and innovative procedural modifications, and regularly lectures throughout the United States and Europe.  He is the Editor of a textbook on Hypertrophic Cardiomyopathy through Springer Publishing. In addition, he routinely serves as Invited Speaker for the American College of Cardiology (ACC), American Heart Association (AHA), Transcatheter Cardiovascular Therapeutics (TCT), and Society for Cardiac Angiography and Intervention (SCAI) Scientific Sessions.